Page last updated: 2024-12-05

dipropyltryptamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dipropyltryptamine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6091
CHEMBL ID1779153
SCHEMBL ID1118996
MeSH IDM0050790

Synonyms (27)

Synonym
dipropyltryptamine
1h-indole-3-ethanamine, n,n-dipropyl-
indole, 3-(2-(dipropylamino)ethyl)-
3-(2-(dipropylamino)ethyl)indole
n,n-dipropyltryptamine
brn 0173122
C16086
n,n-dipropyltryptamine, free base
D-6500
n-[2-(1h-indol-3-yl)ethyl]-n-propylpropan-1-amine
CHEMBL1779153
n-[2-(1h-indol-3-yl)ethyl]-n-propyl-propan-1-amine
A833279
61-52-9
n-(2-(1h-indol-3-yl)ethyl)-n-propylpropan-1-amine
AKOS015967123
unii-s7272vwu50
4-22-00-04323 (beilstein handbook reference)
dpt [experimental drug]
s7272vwu50 ,
FT-0629586
MB02028
SCHEMBL1118996
BOOQTIHIKDDPRW-UHFFFAOYSA-N
DTXSID30209847
n,n-dipropyltryptamine(dpt)
Q2723010

Research Excerpts

Overview

Dipropyltryptamine is a synthetic indolealkylamine first characterized in the 1960s. It has been used psychotherapeutically in humans, but has been studied preclinically only rarely.

ExcerptReferenceRelevance
"Dipropyltryptamine (DPT) is a synthetic indolealkylamine first characterized in the 1960s. "( Binding properties of dipropyltryptamine at the human 5-HT1a receptor.
Burnett, A; Goldstein, E; Parker, KK; Russo, EB; Thiagaraj, HV; Thompson, CM, 2005
)
2.09
"N,N-dipropyltryptamine (DPT) is a synthetic tryptamine hallucinogen which has been used psychotherapeutically in humans, but has been studied preclinically only rarely. "( Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents.
Fantegrossi, WE; Katz, EB; Reissig, CJ; Rice, KC; Winter, JC; Yarosh, HL, 2008
)
1.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID598200Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus.
AID598199Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus.
AID598201Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for Hepatitis B virus2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.56 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index69.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]